001     124344
005     20240228145507.0
024 7 _ |a 10.1093/annonc/mdw446
|2 doi
024 7 _ |a pmid:27687311
|2 pmid
024 7 _ |a 0923-7534
|2 ISSN
024 7 _ |a 1569-8041
|2 ISSN
024 7 _ |a altmetric:12362584
|2 altmetric
037 _ _ |a DKFZ-2017-01223
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Dieter, Sebastian
|0 P:(DE-He78)34c336827b750ba10a020fd62ec4664f
|b 0
|e First author
245 _ _ |a Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
260 _ _ |a Oxford
|c 2017
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1533718930_25748
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Sinonasal carcinomas (SNCs) comprise various rare tumor types that are characterized by marked histologic diversity and largely unknown molecular profiles, yet share an overall poor prognosis owing to an aggressive clinical course and frequent late-stage diagnosis. The lack of effective systemic therapies for locally advanced or metastatic SNC poses a major challenge to therapeutic decision making for individual patients. We here aimed to identify actionable genetic alterations in a patient with metastatic SNC whose tumor, despite all diagnostic efforts, could not be assigned to any known SNC category and was refractory to multimodal therapy.We used whole-exome and transcriptome sequencing to identify a KIT exon 11 mutation (c.1733_1735del, p.D579del) as potentially druggable target in this patient and carried out cancer hotspot panel sequencing to detect secondary resistance-conferring mutations in KIT. Furthermore, as a step towards clinical exploitation of the recently described signatures of mutational processes in cancer genomes, we established and applied a novel bioinformatics algorithm that enables supervised analysis of the mutational catalogs of individual tumors.Molecularly guided treatment with imatinib in analogy to the management of gastrointestinal stromal tumor (GIST) resulted in a dramatic and durable response with remission of nearly all tumor manifestations, indicating a dominant driver function of mutant KIT in this tumor. KIT dependency was further validated by a secondary KIT exon 17 mutation (c.2459_2462delATTCinsG, p.D820_S821delinsG) that was detected upon tumor progression after 10 months of imatinib treatment and provided a rationale for salvage therapy with regorafenib, which has activity against KIT exon 11/17 mutant GIST.These observations highlight the potential of unbiased genomic profiling for uncovering the vulnerabilities of individual malignancies, particularly in rare and unclassifiable tumors, and underscore that KIT exon 11 mutations represent tractable therapeutic targets across different histologies.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antineoplastic Agents
|2 NLM Chemicals
650 _ 7 |a Biomarkers, Tumor
|2 NLM Chemicals
650 _ 7 |a Imatinib Mesylate
|0 8A1O1M485B
|2 NLM Chemicals
650 _ 7 |a Proto-Oncogene Proteins c-kit
|0 EC 2.7.10.1
|2 NLM Chemicals
700 1 _ |a Heining, C.
|0 P:(DE-He78)1464357f7ec5faf677a390a414e50c88
|b 1
700 1 _ |a Agaimy, A.
|b 2
700 1 _ |a Huebschmann, D.
|0 P:(DE-He78)a5218e4871866cd5ab2312e594ca403d
|b 3
700 1 _ |a Bonekamp, D.
|0 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
|b 4
700 1 _ |a Hutter, B.
|0 P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0
|b 5
700 1 _ |a Ehrenberg, K. R.
|0 P:(DE-He78)2768dbb9be6a1f4017a36758dddc731e
|b 6
700 1 _ |a Fröhlich, M.
|0 P:(DE-He78)a15aa7d740f286aad9d8139d515e866c
|b 7
700 1 _ |a Schlesner, M.
|0 P:(DE-He78)f2a782242acf94a3114d75c45dc75b37
|b 8
700 1 _ |a Scholl, C.
|0 P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250
|b 9
700 1 _ |a Schlemmer, H-P
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Wolf, S.
|0 P:(DE-He78)1efb774993effe7a66a6ffc1b1cf9ccb
|b 11
700 1 _ |a Mavratzas, A.
|b 12
700 1 _ |a Jung, C. S.
|b 13
700 1 _ |a Gröschel, S.
|0 P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f
|b 14
700 1 _ |a von Kalle, C.
|0 P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de
|b 15
700 1 _ |a Eils, R.
|0 P:(DE-He78)78b6aa82148e60b4d91e3a37a6d3d9a0
|b 16
700 1 _ |a Brors, B.
|0 P:(DE-He78)fc949170377b58098e46141d95c72661
|b 17
700 1 _ |a Penzel, R.
|b 18
700 1 _ |a Kriegsmann, M.
|b 19
700 1 _ |a Reuss, D. E.
|b 20
700 1 _ |a Schirmacher, P.
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Stenzinger, A.
|b 22
700 1 _ |a Federspil, P. A.
|b 23
700 1 _ |a Weichert, W.
|0 P:(DE-HGF)0
|b 24
700 1 _ |a Glimm, H.
|0 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9
|b 25
700 1 _ |a Fröhling, Stefan
|0 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
|b 26
|e Last author
773 _ _ |a 10.1093/annonc/mdw446
|g Vol. 28, no. 1, p. mdw446 -
|0 PERI:(DE-600)2003498-2
|n 1
|p 142-148
|t Annals of oncology
|v 28
|y 2017
|x 1569-8041
909 C O |p VDB
|o oai:inrepo02.dkfz.de:124344
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)34c336827b750ba10a020fd62ec4664f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)1464357f7ec5faf677a390a414e50c88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)a5218e4871866cd5ab2312e594ca403d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)2768dbb9be6a1f4017a36758dddc731e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)a15aa7d740f286aad9d8139d515e866c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)f2a782242acf94a3114d75c45dc75b37
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)1efb774993effe7a66a6ffc1b1cf9ccb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)78b6aa82148e60b4d91e3a37a6d3d9a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)fc949170377b58098e46141d95c72661
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN ONCOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ANN ONCOL : 2015
920 1 _ |0 I:(DE-He78)G100-20160331
|k G100
|l Translationale Onkologie
|x 0
920 1 _ |0 I:(DE-He78)B080-20160331
|k B080
|l Theoretische Bioinformatik
|x 1
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l Radiologie
|x 2
920 1 _ |0 I:(DE-He78)G200-20160331
|k G200
|l Angewandte Bioinformatik
|x 3
920 1 _ |0 I:(DE-He78)W190-20160331
|k W190
|l Hochdurchsatz-Sequenzierung
|x 4
920 1 _ |0 I:(DE-He78)G102-20160331
|k G102
|l Angewandte Funktionelle Genomik
|x 5
920 1 _ |0 I:(DE-He78)G240-20160331
|k G240
|l Molekulare Leukämogenese
|x 6
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 7
920 1 _ |0 I:(DE-He78)L701-20160331
|k L701
|l DKTK München
|x 8
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G100-20160331
980 _ _ |a I:(DE-He78)B080-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)G200-20160331
980 _ _ |a I:(DE-He78)W190-20160331
980 _ _ |a I:(DE-He78)G102-20160331
980 _ _ |a I:(DE-He78)G240-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)L701-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21